Shares of Ionis Pharmaceuticals (IONS) rallied 6.42% in pre-market trading on Wednesday, following the company's impressive fourth quarter 2024 earnings results and robust guidance for 2025.
For the fourth quarter, Ionis reported revenue of $227 million, handily beating analyst estimates of $137.6 million. The company's loss per share of $0.66 also came in significantly better than the expected loss of $1.10 per share.
Ionis provided an optimistic outlook for 2025, guiding for revenue of over $600 million, above the consensus analyst forecast of $676 million. This stronger-than-expected guidance reflects the company's expanding commercial portfolio and promising pipeline.
Key highlights from Ionis' fourth quarter report include:
Ionis' robust financial performance and promising pipeline catalysts, including several potentially transformational medicines, appear to have fueled the stock's surge in pre-market trading on Wednesday. Investors are betting on the company's evolution into a fully integrated commercial-stage biotech with a diverse revenue stream.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.